Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis

ALK receptor tyrosine kinase has been shown to be a therapeutic target in neuroblastoma. Germline ALK activating mutations are responsible for the majority of hereditary neuroblastoma and somatic ALK activating mutations are also frequently observed in sporadic cases of advanced NB. Crizotinib, a fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yongfeng, Wang, Long, Guan, Shan, Cao, Wenming, Wang, Hao, Chen, Zhenghu, Zhao, Yanling, Yu, Yang, Zhang, Huiyuan, Pang, Jonathan C., Huang, Sophia L., Akiyama, Yo, Yang, Yifan, Sun, Wenjing, Xu, Xin, Shi, Yan, Zhang, Hong, Kim, Eugene S., Muscal, Jodi A., Lu, Fengmin, Yang, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726162/
https://www.ncbi.nlm.nih.gov/pubmed/26786851
http://dx.doi.org/10.1038/srep19423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726162/
https://www.ncbi.nlm.nih.gov/pubmed/26786851
http://dx.doi.org/10.1038/srep19423

Ejemplares similares